Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FMT and Vedolizumab Combination in UC
NCT04231110Phase 4Completed
- Sponsor
- McMaster University
- Start
- May 2021
- Primary completion
- Nov 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of allogeneic fecal microbiota in ulcerative colitis (UC), sponsored by McMaster University. Primary endpoint: Clinical remission at Week 6. Started May 2021; status: completed.
02
Drugs
allogeneic fecal microbiota
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04231110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231110.